Evenity (Romosozumab) Medicare Advantage Coverage: What You Actually Pay in 2026

Why Medicare Advantage Handles Evenity Differently Than Part D

Evenity is a subcutaneous injection administered by a healthcare provider, which places it under the Part B medical benefit rather than the Part D pharmacy benefit on most Medicare Advantage plans. This distinction matters. Part B coverage means your costs are tied to the plan's medical coinsurance structure, not the pharmacy tier copay schedule. For a drug with a wholesale acquisition cost near $1,825 per dose, the coinsurance model produces a very different bill than a flat-tier copay would.

Under Original Medicare Part B, the standard cost-sharing is 20% of the Medicare-approved amount after the annual Part B deductible ($257 in 2025). Medicare Advantage plans can modify this structure. Some MA plans cap specialist visit copays, others apply percentage coinsurance to Part B drugs, and a growing number use step-therapy edits that require documentation of a failed oral bisphosphonate before approving an anabolic agent like romosozumab [1].

According to the American Association of Clinical Endocrinology (AACE) 2020 guidelines, romosozumab is recommended as first-line therapy for patients at "very high" fracture risk, defined by recent fracture, T-score below -3.0, or high FRAX probability. Many MA plans have adopted variations of these criteria for prior authorization decisions.

A 2023 analysis published in the Journal of Bone and Mineral Research found that among commercially insured and Medicare patients prescribed romosozumab, roughly 30% experienced initial claim denials, with the majority overturned on appeal when adequate documentation was submitted [2]. The denial rate underscores why understanding your specific MA plan's criteria matters before your provider submits that first claim.

What Prior Authorization Looks Like for Romosozumab on MA Plans

Nearly every Medicare Advantage plan requires prior authorization before covering Evenity. The process is not optional. Your provider's office submits clinical documentation to the plan, and a utilization management team reviews it against the plan's coverage criteria. Approvals typically arrive within 5 to 15 business days, though urgent requests can be expedited.

The documentation package most MA plans expect includes four components: a DXA scan showing a T-score of -2.5 or lower at the lumbar spine, femoral neck, or total hip; a clinical history of osteoporotic fracture or high FRAX score; evidence that the patient has either tried and failed oral bisphosphonate therapy or has a documented contraindication to it; and cardiovascular risk screening confirming no history of myocardial infarction or stroke within the preceding 12 months [3].

That last requirement exists because of the FDA's boxed warning on Evenity. The ARCH trial (N=4,093) compared romosozumab to alendronate and found a statistically significant increase in serious cardiovascular events in the romosozumab arm during the first 12 months (2.5% vs. 1.9%; P=0.049) [4]. MA plans use this data to justify the cardiovascular screening requirement, and some plans require an EKG or cardiology clearance letter before granting approval.

"The boxed warning doesn't mean romosozumab is contraindicated in all patients with cardiovascular risk factors. It means we need to weigh that risk against the fracture risk," noted the Endocrine Society's 2020 osteoporosis management guidelines, which recommend shared decision-making for patients with both high fracture and moderate cardiovascular risk [5].

If your plan denies the prior authorization, you have formal appeal rights under Medicare regulations. The first-level appeal goes back to the MA plan, and if that fails, an independent review entity handles the second level. Keep every piece of documentation. Successful appeals almost always include a letter of medical necessity from the prescribing physician that directly addresses each denial reason.

Your Actual Out-of-Pocket Costs on Medicare Advantage

The number on your explanation of benefits depends on your specific MA plan's cost-sharing design. Three scenarios cover most enrollees.

Scenario 1: Coinsurance-based plans. Many MA plans apply 20% coinsurance to Part B drugs. On a $1,825 dose, that is $365 per injection and $4,380 over the full 12-dose course. Some plans cap Part B drug coinsurance at a maximum out-of-pocket amount, which can reduce late-course costs.

Scenario 2: Copay-based plans. A smaller number of MA plans assign flat copays to provider-administered drugs. These copays range from $50 to $250 per injection depending on the plan tier and network status of the administering provider. Over 12 months, that translates to $600 to $3,000 total.

Scenario 3: Plans with annual out-of-pocket maximums. All MA plans must have an annual out-of-pocket maximum (MOOP). In 2025, the CMS-set ceiling is $8,850 for in-network services, though most MA plans set their MOOP lower. If you are already approaching your MOOP from other medical spending, Evenity injections later in the year may cost you nothing beyond the cap [6].

One critical variable: whether your provider administers the injection in-office or refers you to an infusion center. In-network specialist office visits typically carry lower cost-sharing than outpatient hospital infusion departments. A single Evenity injection billed under a hospital outpatient facility fee can cost 40% to 60% more in total charges than the same injection in a physician's office, and your coinsurance percentage applies to that higher base amount. Ask your provider's billing department which site of service your plan favors before starting treatment.

The Medicare Payment Advisory Commission (MedPAC) has noted persistent site-of-service cost disparities for Part B drugs. For romosozumab specifically, the average Medicare-allowed amount in a physician office setting runs approximately $1,800 to $1,900 per injection, while the hospital outpatient department charge can exceed $2,400 when facility fees are included.

Step Therapy Requirements and How to Manage Them

Step therapy is the most common barrier MA enrollees face when trying to access romosozumab. The logic is straightforward from the plan's perspective: oral bisphosphonates like alendronate cost $15 to $30 per month, while romosozumab costs $1,825 per month. Plans want documentation that the cheaper option was tried first.

The AACE/ACE guidelines push back against rigid step therapy for very-high-risk patients, arguing that starting with an anabolic agent followed by an antiresorptive produces better long-term fracture risk reduction than starting with a bisphosphonate alone [7]. The FRAME trial (N=7,180) showed that romosozumab for 12 months followed by denosumab reduced new vertebral fractures by 75% compared to placebo followed by denosumab at 24 months [8].

"Sequential therapy beginning with an anabolic agent is the preferred approach for patients at very high fracture risk," stated the AACE 2020 clinical practice guidelines [7]. This language gives your provider ammunition for step-therapy override requests.

To request a step-therapy exception on an MA plan, your provider needs to submit a formal exceptions request. The strongest cases include: a recent fragility fracture (within 24 months) despite bisphosphonate adherence; documented gastrointestinal intolerance to oral bisphosphonates (esophagitis, Barrett's esophagus, stricture); inability to remain upright for 30 minutes post-dose due to mobility limitations; or continued bone density decline on bisphosphonate therapy as documented by serial DXA scans.

Plans must respond to standard exception requests within 72 hours and expedited requests within 24 hours under CMS Medicare Advantage regulations. If your fracture risk is imminent, your provider should submit the expedited pathway.

Amgen's Patient Assistance Programs

Amgen operates two primary programs that can reduce or eliminate your Evenity costs. The programs have different eligibility rules, and which one applies to you depends on your insurance status and income.

Amgen Assist 360. This is the umbrella patient support program. For Medicare Advantage enrollees, the program provides navigation assistance (helping with prior authorization paperwork), copay support information, and connections to independent charitable foundations that may offer copay grants. Amgen cannot legally offer direct copay assistance to Medicare beneficiaries due to the federal Anti-Kickback Statute, but the program can direct you to independent foundations that are compliant [9].

Amgen Safety Net Foundation. For patients with household income at or below 400% of the federal poverty level ($62,400 for an individual in 2025), the Safety Net Foundation provides Evenity at no cost. This applies to both uninsured and underinsured patients, including some Medicare enrollees who face high out-of-pocket costs. Eligibility is reassessed annually.

Several independent foundations also provide copay assistance for osteoporosis medications. The HealthWell Foundation, the Patient Access Network (PAN) Foundation, and the Assistance Fund periodically open osteoporosis-specific funds. These funds open and close based on donation cycles. Call early in the calendar year, as funding is often depleted by Q3. Your provider's office or a specialty pharmacy coordinator can monitor fund availability and submit applications on your behalf.

Comparing Evenity Costs to Alternative Osteoporosis Therapies

Understanding where romosozumab sits in the cost hierarchy helps frame the coverage conversation with your MA plan and your physician.

Oral alendronate (generic Fosamax) runs $10 to $30 per month on most Medicare Part D formularies. Zoledronic acid (Reclast), an IV bisphosphonate given once yearly, costs approximately $1,200 per infusion under Part B, with similar coinsurance rules to Evenity [10]. Denosumab (Prolia), a subcutaneous injection given every six months, costs roughly $1,600 to $1,900 per injection under Part B. Teriparatide (Forteo), a daily self-injection anabolic agent, costs approximately $3,600 per month under Part D, though biosimilar versions have begun to lower this.

The ARCH trial demonstrated that romosozumab followed by alendronate reduced clinical fractures by 27% and hip fractures by 38% compared to alendronate alone over a median follow-up of 33 months (P<0.001 for clinical fractures) [4]. For patients with recent vertebral fracture, the number needed to treat (NNT) to prevent one additional clinical fracture was 12 over the treatment course. That NNT compares favorably to most osteoporosis interventions.

When discussing romosozumab with your MA plan, framing the cost in terms of fracture prevention is often more persuasive than discussing bone density numbers alone. A hip fracture in a Medicare patient costs the system an average of $35,000 to $45 to 000 in acute and post-acute care within the first year [11]. Twelve doses of romosozumab at full price total roughly $21,900. The cost-effectiveness argument is straightforward for very-high-risk patients.

The Cardiovascular Screening Your Plan Will Require

The FDA's boxed warning on Evenity is the single biggest clinical consideration for MA plan coverage. It reads: "Romosozumab may increase the risk of myocardial infarction, stroke, and cardiovascular death. Do not initiate in patients who have had a myocardial infarction or stroke within the preceding year" [3].

The ARCH trial data behind this warning showed 50 major adverse cardiovascular events (MACE) in the romosozumab group versus 38 in the alendronate group during the 12-month double-blind period. This imbalance was not seen in the FRAME trial, which compared romosozumab to placebo (rather than alendronate) and excluded patients with recent CV events [8].

The discrepancy between the two trials has generated ongoing debate. A 2021 meta-analysis in the Journal of Clinical Endocrinology and Metabolism pooled data from both trials and concluded that the cardiovascular signal remains uncertain but warrants caution in patients with established atherosclerotic disease [12].

What this means for your MA coverage: expect your plan to require documentation of cardiovascular history. Some plans accept a signed attestation from the prescriber. Others require a cardiology consultation note or a recent stress test. If you have no cardiovascular history and no major risk factors, the screening requirement is usually satisfied by your prescriber's clinical note. If you have established cardiovascular disease, many MA plans will deny coverage for romosozumab, and the appeal pathway is narrow given the boxed warning.

Practical Steps to Get Evenity Covered in 2026

The following sequence gives you the highest probability of a clean approval.

Step 1: Confirm your MA plan's formulary status. Call the number on the back of your MA card and ask specifically whether romosozumab is covered under the medical benefit or pharmacy benefit, and what the prior authorization criteria are. Request a copy of the coverage determination criteria in writing.

Step 2: Gather documentation before your provider submits the PA. You need a DXA scan from the past 24 months, a complete fracture history, a list of prior osteoporosis medications with dates and reasons for discontinuation, and a cardiovascular history summary. Having everything ready before submission prevents delays.

Step 3: Ask your provider to submit a letter of medical necessity alongside the PA. This letter should reference the AACE very-high-risk criteria and explain why romosozumab is clinically preferred over alternative agents for your specific situation.

Step 4: Contact Amgen Assist 360 at 1-833-EVENITY (1-833-383-6489). They assign a case manager who can help track the PA, identify copay assistance options, and connect you with the Safety Net Foundation if your income qualifies.

Step 5: If denied, appeal within 60 days. Include updated clinical documentation and any new fracture events or bone density results. The CMS Medicare Advantage appeals process guarantees you at least two levels of internal review and an independent external review [6].

Romosozumab treatment is time-limited to 12 monthly doses, after which patients transition to an antiresorptive agent like denosumab or zoledronic acid. This finite course means the total financial commitment is predictable, which can help with planning your copay assistance applications and understanding when you will reach your plan's out-of-pocket maximum.